Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study
Top Cited Papers
- 21 June 2007
- journal article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 8 (7), 595-602
- https://doi.org/10.1016/s1470-2045(07)70175-4
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Myxoid/round cell and pleomorphic liposarcomasCancer, 2007
- Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcomaEuropean Journal Of Cancer, 2006
- Differential sensitivity of liposarcoma subtypes to chemotherapyEuropean Journal Of Cancer, 2005
- Ecteinascidin-743 (ET-743) for Chemotherapy-Naive Patients With Advanced Soft Tissue Sarcomas: Multicenter Phase II and Pharmacokinetic StudyJournal of Clinical Oncology, 2005
- Phase II and Pharmacokinetic Study of Ecteinascidin 743 in Patients With Progressive Sarcomas of Soft Tissues Refractory to ChemotherapyJournal of Clinical Oncology, 2004
- Phase II Study of Ecteinascidin-743 in Advanced Pretreated Soft Tissue Sarcoma PatientsJournal of Clinical Oncology, 2004
- Consistent evidence of activity of ecteinascidin (ET-743) in pretreated, advanced soft tissue sarcoma (ASTS): results from a pooled analysis of three pivotal phase II clinical trials (p2ct) and safety profile of a 24 h infusion scheduleEuropean Journal Of Cancer, 2001
- A Novel FUS/CHOP Chimera in Myxoid LiposarcomaBiochemical and Biophysical Research Communications, 2000
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- Characteristics of genomic breakpoints in TLS-CHOP translocations in liposarcomas suggest the involvement of Translin and topoisomerase II in the process of translocationOncogene, 1999